Morphic Therapeutic is leading the development of a new generation of oral integrin drugs, informed by decades of world-leading expertise and a unique integrin discovery platform. Morphic believes oral drugs targeting the integrin protein family can transform the treatment paradigm for patients suffering from serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. 8/16/24- Acquired by LLY including its assets.